journal article·2026-06Open access

scResponse: A Rank‐Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single‐Cell Data

Qi Dong, Haijun Huang, Yuxiu Wang, Bo Jiang, Yuzheng Chen, Huanhuan Xu, Jing Ren, Shengnan Guo, Tianhao Li, Mingjie Zhang, Tianyu Zhai, Wenbo Yang, Kaidong Liu, Cheng Lyu, Jingxuan Kang, Mingshuo Zhang, Yupeng Lu, Binghui Si, Shujun Cao, Dandan Xu, Zong Chen, Dapeng Hao

Advanced Science· Volume 13· Issue 31

Abstract

ABSTRACT Immunotherapy has shown great promise in cancer treatment, yet many patients fail to achieve long‐term efficacy. Single‐cell sequencing is a powerful technique for understanding how cellular diversity affects treatment outcomes; however, there remains a lack of robust methods for evaluating immunotherapy efficacy at single‐cell resolution. In this study, we present scResponse, an efficient algorithm that quantifies single‐cell responses to immunotherapy. scResponse captures subtle influences of diverse cellular subtypes and states on immunotherapy efficacy, including the effects of vascular normalization states of vascular cells, polarization of macrophages, terminal exhaustion of CD8 + T cells, and the opposing impacts from distinct fibroblast subtypes. By linking therapeutic response to single‑cell states, scResponse enables to delineate how distinct biological processes shape cellular states to drive divergent therapeutic outcomes. Integrated analysis across cancers identified key metabolic pathways associated with responsive states of tumor cells, including glyoxylate and dicarboxylate metabolism as immunotherapy‐sensitizing and retinol metabolism as suppressing it. As a proof‐of‐concept, the opposing roles of glyoxylate and retinol metabolism was validated using tumor‑CD8 + T cell co‐culture assays and in vivo mouse models. Thus, scResponse is an effective tool for mapping immunotherapy efficacy to single‐cell states, enabling mechanistic insights and target discovery for developing novel immunotherapy sensitization strategies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Single-cell and spatial transcriptomics · Cancer Immunotherapy and Biomarkers · Ferroptosis and cancer prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Harbin Medical University Cancer Hospital Harbin Medical University Harbin China

Key Laboratory of Molecular Oncology of Heilongjiang Province Harbin China

School of Basic Medical Sciences Harbin Medical University Harbin China

School of Intelligent Medicine and Technology Big Data Research Center Hainan Engineering Research Center for Health Big Data Hainan Medical University Hainan China

Department of Hematology The Second Affiliated Hospital of Harbin Medical University Harbin China

Department of Systems Biology College of Bioinformatics Science and Technology Harbin Medical University Harbin China

Center for Endemic Disease Control Chinese Center for Disease Control and Prevention Harbin Medical University Harbin China

National Health Commission Key Laboratory of Etiology and Epidemiology Harbin Medical University Harbin China

Joint Key Laboratory of Endemic Diseases Harbin Medical University Guizhou Medical University Xi'an Jiaotong University Harbin China

Department of Phase 1 Trials Center Harbin Medical University Cancer Hospital Harbin Medical University Harbin China

Funding

National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (38)

Show source-provided references
1. 10.3390/curroncol2905024710.3390/curroncol29050247 ↗
2. 10.3390/pharmaceutics1504114310.3390/pharmaceutics15041143 ↗
3. 10.1186/s13045‐023‐01494‐610.1186/s13045‐023‐01494‐6 ↗
4. 10.1186/s12943‐025‐02426‐310.1186/s12943‐025‐02426‐3 ↗
5. 10.1111/imm.1358810.1111/imm.13588 ↗
6. 10.1038/s41392‐020‐00377‐310.1038/s41392‐020‐00377‐3 ↗
7. 10.1016/j.crmeth.2023.10064310.1016/j.crmeth.2023.100643 ↗
8. 10.1038/s41698‐025‐00883‐z10.1038/s41698‐025‐00883‐z ↗
9. 10.1016/j.tranon.2024.10191010.1016/j.tranon.2024.101910 ↗
10. 10.1016/j.csbj.2020.10.00710.1016/j.csbj.2020.10.007 ↗
11. 10.1093/nargab/lqae12410.1093/nargab/lqae124 ↗
12. 10.1172/JCI9119010.1172/JCI91190 ↗
13. 10.1038/s41586‐020‐2155‐610.1038/s41586‐020‐2155‐6 ↗
14. 10.1038/s41591‐019‐0628‐710.1038/s41591‐019‐0628‐7 ↗
15. 10.1038/nature1401110.1038/nature14011 ↗
16. 10.1016/j.medj.2023.07.00610.1016/j.medj.2023.07.006 ↗
17. 10.1038/ng118010.1038/ng1180 ↗
18. 10.1016/j.ccell.2022.10.00810.1016/j.ccell.2022.10.008 ↗
19. 10.1038/nature2172410.1038/nature21724 ↗
20. 10.1136/jitc‐2024‐01053410.1136/jitc‐2024‐010534 ↗
21. 10.1038/s41392‐023‐01622‐110.1038/s41392‐023‐01622‐1 ↗
22. 10.1016/j.canlet.2022.21604310.1016/j.canlet.2022.216043 ↗
23. 10.1182/blood‐2009‐10‐24885610.1182/blood‐2009‐10‐248856 ↗
24. 10.1074/jbc.M112.41354210.1074/jbc.M112.413542 ↗
25. 10.1002/dvg.2353910.1002/dvg.23539 ↗
26. 10.1093/hmg/ddp58410.1093/hmg/ddp584 ↗
27. 10.1038/s41401‐024‐01304‐w10.1038/s41401‐024‐01304‐w ↗
28. 10.1016/j.cell.2020.02.04210.1016/j.cell.2020.02.042 ↗
29. 10.1038/s41590‐025‐02376‐410.1038/s41590‐025‐02376‐4 ↗
30. 10.1016/j.ccell.2024.02.00410.1016/j.ccell.2024.02.004 ↗
31. 10.1016/j.xcrm.2025.10241610.1016/j.xcrm.2025.102416 ↗
32. 10.1016/j.trecan.2024.01.01010.1016/j.trecan.2024.01.010 ↗
33. 10.1038/s43018‐022‐00356‐310.1038/s43018‐022‐00356‐3 ↗
34. 10.1126/science.aax024910.1126/science.aax0249 ↗
35. 10.1038/s41586‐019‐0969‐x10.1038/s41586‐019‐0969‐x ↗
36. 10.1038/s41467‐021‐21246‐910.1038/s41467‐021‐21246‐9 ↗
37. 10.1158/2159‐8290.CD‐21‐031610.1158/2159‐8290.CD‐21‐0316 ↗
38. 10.1038/nmeth.446310.1038/nmeth.4463 ↗